AION Labs venture studio
Venture-studio ownership and governance not published · Israel / global pharma · Checking status
AION Labs is an AI-enabled drug-discovery venture studio backed by AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS. It provides pre-seed capital, pharma access, co-development, pilots, and operating support, but no current generic founder intake, standard cash amount, studio ownership, or cohort calendar is published.
Tier 3israelbiotechstudio
ApplyOfficial siteOpen in the live directory
Program intake
We are checking the program's authoritative source for the current application status.
Key facts
| Check size | Pre-seed capital; standard amount not published |
| Terms | Venture-studio ownership and governance not published |
| Stage | AI-enabled drug discovery company formation |
| Applications | Checking status |
| Location | Israel / global pharma |
| Remote friendly | No |
| Warm intro needed | No — open application |
| Sectors | ai, bio, pharma |
| Status | unknown |
Always confirm on the official page before applying — dates and terms change.
Background
The studio builds companies around pharma-defined challenges and aims to reach meaningful pilots in under eighteen months. That partner access can be unusually valuable for scientific founders, while the venture-studio structure makes IP, governance, founder vesting, and ownership central diligence items.
How the application really works
Follow AION Labs' challenge and company-formation calls rather than expecting a rolling accelerator form. Confirm the role, company, scientific challenge, and ownership package for the specific opportunity.
Tips
- Read the cited current official page before applying because program dates and terms are volatile.
- State fit with the documented stage, geography, and attendance model; do not rely on an aggregator's old terms.
- Ask for the complete investment, fee, and follow-on documents when the public page does not publish them.
Watch out for
- Pre-seed capital and studio resources are promised; cash amount, founder/studio equity, vesting, IP, board rights, and follow-on rights are not publicly standardized.
- No current generic founder call, standard cash amount, studio equity split, fee, cohort, or deadline is published on the checked page.
Track record
- The official site documents strategic backing from AstraZeneca, Merck, Pfizer, Teva, AWS, and venture investors; it does not publish a current aggregate exit or follow-on figure.
No generic application count, cohort size, or acceptance rate.
Frequently asked questions
- Is this program currently accepting applications?
- Follow AION Labs' challenge and company-formation calls rather than expecting a rolling accelerator form. Confirm the role, company, scientific challenge, and ownership package for the specific opportunity.
- What are the current economics?
- Pre-seed capital and studio resources are promised; cash amount, founder/studio equity, vesting, IP, board rights, and follow-on rights are not publicly standardized.
- How large and long is the program?
- Challenge-specific company creation; current venture and founder intake counts not published. Venture creation, pharma co-development, AWS infrastructure, pre-seed capital, and pilot support.
- Can founders participate remotely?
- Israel-centered studio and pharma collaboration; no fully remote promise.
- What happens after the program?
- Pharma pilot and investor access; no guaranteed standardized follow-on amount.
Related accelerators
Sources
- aionlabs.com — Current venture-studio model, strategic partners, pre-seed support, pharma access, co-development, and pilot positioning (checked 2026-08-10)